Celgene

Thomas O. Daniel, M.D. has been appointed president of Celgene Research, responsible for leading the discovery, preclinical and early stage clinical programs for the company worldwide. Dr. Daniel has more than 20 years of medical and pharmaceutical research experience. He most recently served as the chief scientific officer at Ambryx, Inc., a biotechnology company focused on discovering and developing protein-based therapeutics. Prior to that, Dr. Daniel was vice president of research at Amgen, where he served as research site head for Amgen Seattle, as inflammation therapeutic area head, and on R&D portfolio review boards. Prior to Amgen’s acquisition of Immunex, Dr. Daniel was senior vice president of discovery research at Immunex, where he consolidated and built programs in oncology and vascular biology.

“We are very pleased to welcome Dr. Daniel to Celgene,” said Sol J. Barer, Ph.D., chief executive officer at Celgene Corp. “Dr. Daniel’s extensive experience in oncology and immunology, coupled with a proven track record of building and leading research and development teams, provides us with valuable skills to advance our promising proprietary pipeline that embodies the future of Celgene.”

Also, David W. Gryska joined the company as chief financial officer and will lead the worldwide finance organization with responsibility for accounting and reporting, strategic planning and analysis, treasury, tax, audit, and corporate communications. Mr. Gryska has extensive business experience having served as a chief financial officer of public companies for more than 10 years, most recently at Scios Inc., a biopharmaceutical company that was acquired by Johnson & Johnson. Earlier in his career, Mr. Gryska spent 11 years at Ernst & Young where he rose to partner and was responsible for managing audit and consulting services for private and public held biotechnology and healthcare companies.

“We are very pleased to have David join our senior management team at Celgene during a period of such rapid growth where his business building skills and financial experience will contribute broadly to our finance, operations and global business strategy,” said Dr. Barer.